Log in

NASDAQ:HTBX - Heat Biologics Stock Price, Forecast & News

$0.25
0.00 (0.00 %)
(As of 02/18/2020 08:00 AM ET)
Today's Range
$0.24
Now: $0.25
$0.25
50-Day Range
$0.23
MA: $0.34
$0.51
52-Week Range
$0.23
Now: $0.25
$1.80
Volume729,320 shs
Average Volume1.59 million shs
Market Capitalization$14.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.79 million
Book Value$0.93 per share

Profitability

Net Income$-15,730,000.00
Net Margins-695.62%

Miscellaneous

Employees30
Market Cap$14.36 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.


Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

How were Heat Biologics' earnings last quarter?

Heat Biologics Inc (NASDAQ:HTBX) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 695.62% and a negative return on equity of 88.07%. View Heat Biologics' Earnings History.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Heat Biologics.

What price target have analysts set for HTBX?

3 brokers have issued 1 year price objectives for Heat Biologics' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate Heat Biologics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 2,700.0% from the stock's current price. View Analyst Price Targets for Heat Biologics.

What is the consensus analysts' recommendation for Heat Biologics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Has Heat Biologics been receiving favorable news coverage?

Media coverage about HTBX stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heat Biologics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Heat Biologics.

Are investors shorting Heat Biologics?

Heat Biologics saw a decrease in short interest in January. As of January 15th, there was short interest totalling 469,500 shares, a decrease of 17.8% from the December 31st total of 571,400 shares. Based on an average trading volume of 384,800 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are short sold. View Heat Biologics' Current Options Chain.

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), TherapeuticsMD (TXMD), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Sophiris Bio (SPHS) and TrovaGene (TROV).

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
  • Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor

Who are Heat Biologics' major shareholders?

Heat Biologics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.82%) and Virtu Financial LLC (0.10%). View Institutional Ownership Trends for Heat Biologics.

Which institutional investors are buying Heat Biologics stock?

HTBX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. View Insider Buying and Selling for Heat Biologics.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $0.25.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $14.36 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.

What is Heat Biologics' official website?

The official website for Heat Biologics is http://www.heatbio.com/.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]


MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel